Business
Cannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients
Cannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients\n\n\n\n\n\nCannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients\nPR Newswire\nTEL-AVIV, Israel, January 2, 2018\n\n\n\nTEL-AVIV, Israel, January 2, 2018 /PRNewswire/ --\n\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.\n\n     (Logo: http://mma.prnewswire.com/media/485543/Cannabics_Logo.jpg )\n\n\nThe determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients. The integrated approach brings together cannabinoids research, Genetic markers, CTC counting and detection methods, and a drug sensitivity test for cannabinoids developed by Cannabics Pharmaceuticals. This unique method expands the company's proprietary technology of developing a more precise tool for personalization of cannabinoids based medicine as well as accelerating drug discovery.\n\nAbout Cannabics Pharmaceuticals Inc. \n\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.\n\nDisclaimer: \n\nCertain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as \"believes,\" \"expects,\" \"anticipates,\" \"estimates,\" \"intends,\" \"plans,\" \"targets,\" \"projec...